Caris Life Sciences, Inc. (CAI) Earnings History
Profitable23 years of earnings data (2003–2025) · Positive TTM net income
Loading earnings history...
Caris Life Sciences, Inc. (CAI) Earnings Overview
As of June 22, 2026, Caris Life Sciences, Inc. (CAI) reported trailing twelve-month net income of $34M, reflecting +29.6% year-over-year growth. The company earned $0.12 per diluted share over the past four quarters, with a net profit margin of -66.2%.
Looking at the long-term picture, CAI's historical earnings data spans multiple years. The company achieved its highest annual net income of $79M in fiscal 2018.
Caris Life Sciences, Inc. maintains positive profitability with a gross margin of 66.4%, operating margin of 5.6%, and net margin of -66.2%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including EXAS (-$208M net income, -6.4% margin), ILMN ($853M net income, 19.6% margin), NTRA (-$226M net income, -9.0% margin), CAI has room to improve margins relative to the peer group. Compare CAI vs EXAS →
CAI Earnings vs Peers
Earnings metrics vs comparable public companies
CAI Historical Earnings Data (2003–2025)
22 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$538M | -90.8% | $45M | $-1.90 | -66.2% | 5.6% |
| 2024 | -$282M | +17.4% | -$257M | $-2.70 | -68.4% | -62.4% |
| 2023 | -$341M | -6.4% | -$320M | $-1.82 | -111.5% | -104.4% |
| 2022 | -$321M | -1256.8% | -$316M | $-1.57 | -124.1% | -122.2% |
| 2020 | $28M | -10.6% | $139M | $1.55 | 9.4% | 47.3% |
| 2019 | $31M | -60.5% | $130M | $1.72 | 7.4% | 31.3% |
| 2018 | $79M | +9.1% | $149M | $3.97 | 18.2% | 34.4% |
| 2017 | $72M | +1101.6% | $106M | $3.68 | 20.7% | 30.3% |
| 2016 | $6M | -77.7% | $66M | $0.31 | 2.0% | 22.4% |
| 2015 | $27M | -55.5% | $68M | $1.28 | 10.7% | 27.3% |
| 2014 | $60M | -5.7% | $97M | $2.85 | 26.5% | 42.6% |
| 2013 | $64M | +0.7% | $101M | $2.82 | 30.1% | 47.7% |
| 2012 | $63M | +26.5% | $91M | $3.18 | 36.5% | 52.1% |
| 2011 | $50M | +76.8% | $64M | $2.55 | 39.9% | 51.1% |
| 2010 | $28M | +109.4% | $37M | $1.56 | 36.4% | 47.5% |
| 2009 | $14M | +150.3% | $23M | $0.76 | 20.8% | 35.0% |
| 2008 | -$27M | -240.1% | $44M | $-1.55 | -32.4% | 53.3% |
| 2007 | $19M | +267.6% | $40M | $1.15 | 29.6% | 61.6% |
| 2006 | $5M | -47.6% | $12M | $0.25 | 28.1% | 64.7% |
| 2005 | $10M | +8.2% | $24M | $0.47 | 16.2% | 39.2% |
| 2004 | $9M | +448.4% | $23M | $0.44 | 13.8% | 34.5% |
| 2003 | -$3M | - | $4M | $-0.13 | -5.5% | 7.7% |
Download Data
Export CAI earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
23+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CAI — Frequently Asked Questions
Quick answers to the most common questions about buying CAI stock.
What is CAI earnings per share (EPS)?
CAI trailing twelve-month (TTM) diluted EPS is $0.12, reflecting +29.6% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2003 to 2025 is available in the table on this page.
What is Caris Life Sciences, Inc.'s net income?
Caris Life Sciences, Inc. (CAI) trailing twelve-month net income is $34M as of 2025. Earnings grew +29.6% year-over-year.
Is CAI profitable?
Yes, CAI is profitable with a TTM net income of $34M and a net profit margin of -66.2%.
What is CAI's earnings growth rate?
CAI compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2003 to 2025.
What are CAI's profit margins?
Caris Life Sciences, Inc. net profit margin is -66.2%, operating margin is +5.6%, and gross margin is +66.4%. Below-average margins reflect competitive or cost pressures. Return on Equity is -93.2%.
Is CAI growing earnings?
Yes, CAI earnings are accelerating — EPS growth of +29.6% exceeds the 5-year CAGR of N/A. TTM net income reached $34M. Earnings momentum is strengthening.
What was CAI's best earnings year?
Caris Life Sciences, Inc.'s highest annual net income on record is $79M, achieved in fiscal year 2018. Earnings history on this page spans 2003 to 2025 and includes all annual and quarterly figures.
What were CAI's earnings last quarter?
CAI's most recent reported quarter was Q1 2026. Net income was $-510000.00 with diluted EPS of $-0.00. For a full breakdown of all quarters, see the quarterly earnings table on this page.